Q1 Earnings Estimate for BLFS Issued By HC Wainwright

BioLife Solutions, Inc. (NASDAQ:BLFS) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for BioLife Solutions in a research report issued on Thursday, July 23rd. HC Wainwright analyst Y. Chen forecasts that the medical equipment provider will earn $0.03 per share for the quarter. HC Wainwright has a “Neutral” rating and a $31.00 price objective on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2027 earnings at $0.03 EPS, Q3 2027 earnings at $0.05 EPS and Q4 2027 earnings at $0.05 EPS.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The business had revenue of $27.50 million during the quarter, compared to the consensus estimate of $25.66 million.

Several other brokerages have also recently issued reports on BLFS. TD Cowen cut BioLife Solutions from a “buy” rating to a “hold” rating and cut their target price for the company from $33.00 to $31.00 in a research report on Wednesday. Lake Street Capital cut BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price objective for the company from $33.00 to $31.00 in a research note on Wednesday. Craig Hallum downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a report on Wednesday. Wall Street Zen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Maxim Group downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $31.43.

BioLife Solutions Stock Performance

BLFS stock opened at $29.98 on Friday. The business has a 50-day simple moving average of $26.94 and a two-hundred day simple moving average of $23.55. The company has a market capitalization of $1.46 billion, a P/E ratio of -374.70 and a beta of 1.94. BioLife Solutions has a 52-week low of $17.86 and a 52-week high of $32.23.

Insider Activity

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the sale, the insider owned 4,757,165 shares in the company, valued at $112,744,810.50. This trade represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 1,200,000 shares of company stock worth $28,125,000. Company insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

Institutional investors and hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. increased its stake in BioLife Solutions by 27.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock valued at $125,273,000 after purchasing an additional 1,113,972 shares in the last quarter. Bank of America Corp DE boosted its position in BioLife Solutions by 73.4% in the first quarter. Bank of America Corp DE now owns 904,103 shares of the medical equipment provider’s stock worth $17,250,000 after purchasing an additional 382,776 shares during the last quarter. Capricorn Fund Managers Ltd bought a new stake in shares of BioLife Solutions during the 4th quarter valued at about $9,153,000. Invesco Ltd. grew its stake in shares of BioLife Solutions by 9.2% during the 4th quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock valued at $95,080,000 after purchasing an additional 332,747 shares during the period. Finally, Granahan Investment Management LLC increased its position in shares of BioLife Solutions by 49.7% during the 1st quarter. Granahan Investment Management LLC now owns 722,057 shares of the medical equipment provider’s stock valued at $13,777,000 after purchasing an additional 239,701 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and a $31 price target while forecasting modest earnings growth for BioLife Solutions through 2027, which suggests analysts still see some upside from current levels. HC Wainwright earnings estimates and rating for BioLife Solutions
• Neutral Sentiment: Repligen’s planned acquisition of BioLife Solutions is being framed as strategically positive for Repligen’s cell therapy business, and the deal could provide a clear exit value for BLFS shareholders if completed. Zacks article on Repligen buying BioLife Solutions
• Negative Sentiment: Maxim Group downgraded BioLife Solutions (BLFS) from strong-buy to hold, adding pressure on the stock and signaling less enthusiasm from analysts. Maxim Group downgrade coverage via Zacks
• Negative Sentiment: Kahn Swick & Foti said it is investigating the adequacy of the price and process in BioLife’s proposed sale to Repligen, raising the risk of shareholder litigation or a challenged deal process. BusinessWire investor alert on BioLife Solutions sale investigation
• Negative Sentiment: TD Cowen also downgraded BioLife Solutions (BLFS) to hold, reinforcing the cautious tone around the stock after the acquisition announcement. TD Cowen downgrade on BioLife Solutions

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.